Mary M Horowitz MD MS

Hematologic Oncology

Chief, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin; Chief Scientific Director, Center for International Blood and Marrow Transplant Research

Join to View Full Profile

9200 W Wisconsin Ave# NeoplastMilwaukee, WI 53226
Phone+1 414-805-0700
Fax+1 414-805-0714

Education & Training

Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 1987 - 1989
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1980 - 1984
Medical College of WisconsinClass of 1980

Certifications & Licensure

WI State Medical License 1981 - 2025
American Board of Internal Medicine Internal Medicine

Clinical Trials

Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Start of enrollment: 2008 Oct 01
Completed
Phase 2
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) Start of enrollment: 2008 Dec 01
Completed
Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
Completed
Phase 2
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
Allogeneic Transplant in HIV Patients (BMT CTN 0903) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202) Start of enrollment: 2013 Jun 01
Completed
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Start of enrollment: 2013 Dec 01
Completed
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) Start of enrollment: 2016 Jul 01
Completed
Phase 2
Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) Start of enrollment: 2017 Jul 03
Completed
Phase 2
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Start of enrollment: 2017 Oct 03
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplan...
Stephanie J Lee, Brent Logan, Mary M Horowitz, Jason G Dehn, Joseph Pidala
Journal of Clinical Oncology. 2025-09-18
Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.
Neel S Bhatt, Azra Borogovac, Yvonne A Efebera, Anna DeSalvo, Steven M Devine
Blood Advances. 2025-09-09
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.
Sameem Abedin, Michael J Martens, Javier Bolaños-Meade, Monzr M Al Malki, Qinghua Lian
Blood Advances. 2025-07-22

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica

Abstracts/Posters

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...
Mary M. Horowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Mary M. Horowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML
Mary M. Horowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Mary M. Horowitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Annual NMDP(SM) Gala in New York City Raises over a Half Million Dollars, Enabling More Patients to Receive Life-Saving Cell TherapyMay 6th, 2025
Ryght AI Welcomes the Medical College of Wisconsin to Global Site Network as Their Latest Academic PartnerApril 3rd, 2025
Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicineMay 24th, 2023
Join now to see all

Grant Support

Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.MEDICAL COLLEGE OF WISCONSIN2017–2031
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
Cure Sickle CellMEDICAL COLLEGE OF WISCONSIN2018–2026
A Data Resource For Analyzing Blood And Marrow TransplantsNational Cancer Institute2008–2012
Blood &Marrow Transplant Clinical Trials Network Data Coordinating CenterNational Heart, Lung, And Blood Institute2011
BMT Clinical Research Network Data Coordinating CenterNational Heart, Lung, And Blood Institute2001–2010
Data Resource For Analyzing Blood &Marrow TransplantsNational Cancer Institute2003–2007
AML T-Cell DepletionNational Heart, Lung, And Blood Institute2005
Acute GVHD TreatmentNational Heart, Lung, And Blood Institute2005
PB Vs. BMNational Heart, Lung, And Blood Institute2004–2005
Multiple MyelomaNational Heart, Lung, And Blood Institute2004–2005
Fungal ProphylasixNational Heart, Lung, And Blood Institute2004–2005
Folicular LymphomaNational Heart, Lung, And Blood Institute2004–2005
Data Resource For Analyzing Blood And Marrow TransplantsNational Cancer Institute1998–2002
Cancer Following Bone Marrow TransplantationDivision Of Cancer Epidemiology And Genetics1995–2000
Transplants In Other CancersNational Cancer Institute1995–1998
Transplants In LeukemiaNational Cancer Institute1995–1998
Transplant BiologyNational Cancer Institute1995–1998
Collaborative Bone Marrow Transplant ProgramNational Cancer Institute1994–1998
A Collaborative Bone Marrow Transplant ProgramNational Cancer Institute1992–1993